Clene (CLNN) Inventories, Finished Goods : $0.02 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Clene Inventories, Finished Goods?

Clene's quarterly finished goods stayed the same from Jun. 2024 ($0.01 Mil) to Sep. 2024 ($0.01 Mil) but then increased from Sep. 2024 ($0.01 Mil) to Dec. 2024 ($0.02 Mil).

Clene's annual finished goods stayed the same from Dec. 2022 ($0.01 Mil) to Dec. 2023 ($0.01 Mil) but then increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.02 Mil).

Clene Inventories, Finished Goods Historical Data

The historical data trend for Clene's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Inventories, Finished Goods Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventories, Finished Goods

Get a 7-Day Free Trial

0.12

0.02

0.01

0.02

Clene Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Inventories, Finished Goods	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.02

Clene Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Clene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Clene Inc (NAS:CLNN) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

84C0:Germany

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

Executives

General Resonance Llc	10 percent owner	6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
David J Matlin	director
Mark Mortenson	officer: Chief Science Officer	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Robert Dee Etherington	director, officer: Chief Executive Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Matthew Kiernan	director	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
John Henry Stevens	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Alison Mosca	director	26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay	director	177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
Robert Glanzman	officer: Chief Medical Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown	officer: Chief Financial Officer	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Reed N Wilcox	director	9667 S SILVERBERRY CIRCLE, HIGHLANDS RANCE CO 80129
Shalom Jacobovitz	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121